Navigation Links
S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
Date:5/4/2010

SINGAPORE and EMERYVILLE, Calif., May 4 /PRNewswire-FirstCall/ -- S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

Onyx will provide $20 million in funding to broaden and accelerate the existing development program for both compounds.  The program will be expanded to include new indications for hematologic malignancies and myeloproliferative disorders.  S*BIO will continue to perform the clinical development of SB1518 (ONX 0803) and preclinical through clinical development of SB1578 (ONX 0805).

"We have made significant progress in the development of our novel JAK2 inhibitors and the new funding by Onyx further validates the strength of our collaboration and underscores the success of our joint programs," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Advancing SB1518 and SB1578 into new indications will generate greater value in our assets and is expected to expedite future commercialization."

"We believe these JAK2 inhibitors have potential as important cancer therapeutics, and it is to the advantage of patients affected by these diseases to accelerate and broaden their clinical testing into multiple hematologic and myeloproliferative disorders," said N. Anthony Col
'/>"/>

SOURCE S*BIO Pte Ltd; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
2. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Completes US$26 Million Equity Financing
5. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
6. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
7. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... as the "holy grail" of nanoscience, researchers at the ... the first time used DNA to guide the creation ... dimensions measured in billionths of a meter). The ability ... functional materials that take advantage of the unique properties ...
... 30 Monogram,Biosciences, Inc., (Nasdaq: MGRM ) announced ... 7, 2008 at 4:30 p.m. (Eastern Time) to discuss,fourth ... for 2008.,The call will be hosted by Mr. William ... in the live teleconference, please call (877) 545-1409,or (719) ...
... (TSX: HBP / Frankfurt: WKN 918864), AURORA, ... that at the Company,s Annual General Meeting held ... resolutions presented by,management, appointing KPMG LLP as auditor, ... Slawomir Majewski, and Gordon Lickrish as,directors, and approving ...
Cached Biology Technology:DNA technique yields 3-D crystalline organization of nanoparticles 2DNA technique yields 3-D crystalline organization of nanoparticles 3Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call 2Helix BioPharma shareholders vote in favour of management 2
(Date:7/9/2014)... delivered by Caesarean section have a different intestinal flora than ... why this is the case and what it means for ... Medical Sciences therefore decided to scrutinise the impact of birth ... of newborn mouse pups. , The study ... lower number of cells that strengthen the immune system, says ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2USF study: Amphibians can acquire resistance to deadly fungus 2
... an important discovery in the interdisciplinary study of split-brain research. ... left and right hemispheres. Split-brain research has been conducted ... processing is largely located in the left side of the ... an area processed by the right side of the ...
... between partners is a fundamental requisite in agricultural biotech ... from a four year study into what built or ... In a special supplement published in the UK-based journal ... from the Sandra Rotman Centre at the University Health ...
... been considered a major risk factor for cardiovascular disease. ... but the mechanisms of how arteries stave off hardening ... Perelman School of Medicine, University of Pennsylvania, Wistar Institute, ... the protein apolipoprotein E (apoE) plays a major role ...
Cached Biology News:UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 2UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 3UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 4Study details essential role of trust in agricultural biotech partnerships 2Study details essential role of trust in agricultural biotech partnerships 3Study details essential role of trust in agricultural biotech partnerships 4Study details essential role of trust in agricultural biotech partnerships 5Study details essential role of trust in agricultural biotech partnerships 6Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3
... The Cytomics FC 500 Series ... equipped with the most advanced ... Series delivers flexible testing, powerful ... features that help researchers optimize ...
... irreversibly crosslinked to protein G-agarose beads which ... from heart mitochondria. Also included are 2 ... immunocapture. ,The pyruvate dehydrogenase complex (PDH) immunocapture ... amounts of tissue. This facilitates the subsequent ...
... delivery using PULSin may be superior to ... unlike traditional transfection, with PULSin you can ... and time course of proteins in cells. ... more information than traditional RNA interference experiments. ...
... delivery using PULSin may be superior to ... unlike traditional transfection, with PULSin you can ... and time course of proteins in cells. ... more information than traditional RNA interference experiments. ...
Biology Products: